These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies. Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538 [TBL] [Abstract][Full Text] [Related]
23. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622 [TBL] [Abstract][Full Text] [Related]
24. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593 [TBL] [Abstract][Full Text] [Related]
25. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW; JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240 [TBL] [Abstract][Full Text] [Related]
27. Neointimal Healing Evaluated by Optical Coherence Tomography after Drug-Eluting Absorbable Metal Scaffold Implantation in de novo Native Coronary Lesions: Rationale and Design of the Magmaris-OCT Study. Karjalainen P; Paana T; Sia J; Nammas W Cardiology; 2017; 137(4):225-230. PubMed ID: 28467998 [TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo evaluation of a novel bioresorbable magnesium scaffold with different surface modifications. Menze R; Wittchow E J Biomed Mater Res B Appl Biomater; 2021 Sep; 109(9):1292-1302. PubMed ID: 33386677 [TBL] [Abstract][Full Text] [Related]
29. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647 [TBL] [Abstract][Full Text] [Related]
30. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry. Wlodarczak A; Montorsi P; Torzewski J; Bennett J; Starmer G; Buck T; Haude M; Moccetti M; Wiemer M; Lee MK; Verheye S EuroIntervention; 2023 Jun; 19(3):232-239. PubMed ID: 37226676 [TBL] [Abstract][Full Text] [Related]
31. The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome. Włodarczak A; Łanocha M; Szudrowicz M; Barycki M; Gosiewska A; Kulczycki JJ; Lesiak M; Doroszko A; Rola P J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300332 [TBL] [Abstract][Full Text] [Related]
32. Magnesium bioresorbable scaffold (Magmaris) versus polymer biodegradable ultrathin drug-eluting stent (Ultimaster) in acute coronary syndrome. Mid-term outcomes (2 years). Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Doroszko A; Lesiak M Postepy Kardiol Interwencyjnej; 2024 Mar; 20(1):67-75. PubMed ID: 38616930 [TBL] [Abstract][Full Text] [Related]
33. Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives. Rapetto C; Leoncini M J Thorac Dis; 2017 Aug; 9(Suppl 9):S903-S913. PubMed ID: 28894596 [TBL] [Abstract][Full Text] [Related]
35. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent. Barkholt TØ; Webber B; Holm NR; Ormiston JA Catheter Cardiovasc Interv; 2020 Dec; 96(7):E674-E682. PubMed ID: 31710149 [TBL] [Abstract][Full Text] [Related]
36. Long-term results of BVS implantation: a focus on safety and efficacy of the bioresorbable technology. DEN Dekker WK; VAN Geuns RJ; Diletti R Minerva Cardioangiol; 2016 Aug; 64(4):462-72. PubMed ID: 27175976 [TBL] [Abstract][Full Text] [Related]